

# Carriage of Plasmidic AmpC Beta-Lactamase Producing *Escherichia coli* in Cattle and Sheep and Characterisation of the Isolates in Terms of Antibiogram Profiles, Phylogeny and Virulence <sup>[1]</sup>

Faruk PEHLIVANOGLU <sup>1,a</sup> Dilek OZTURK <sup>1,b</sup> Hulya TURUTOGLU <sup>1,c</sup>

<sup>[1]</sup> The part of the data presented in this article was presented as oral presentation in Ecology and Safety 2019-28<sup>th</sup> International Conference (28 June-02 July 2019), Burgas, Bulgaria

<sup>1</sup> Department of Microbiology, Faculty of Veterinary Medicine, Mehmet Akif Ersoy University, TR-15030 Burdur - TURKEY  
ORCID: <sup>a</sup> 0000-0001-9358-8007; <sup>b</sup> 0000-0002-9643-8570; <sup>c</sup> 0000-0003-0011-8597

Article ID: KVFD-2019-23541 Received: 30.10.2019 Accepted: 20.02.2020 Published Online: 01.03.2020

## How to Cite This Article

**Pehlivanoglu F, Ozturk D, Turutoglu H:** Carriage of plasmidic AmpC beta-lactamase producing *Escherichia coli* in cattle and sheep and characterisation of the isolates in terms of antibiogram profiles, phylogeny and virulence. *Kafkas Univ Vet Fak Derg*, 26 (4): 469-476, 2020. DOI: 10.9775/kvfd.2019.23541

## Abstract

AmpC type beta-lactamase enzyme production by *Escherichia coli* confers resistance to penicillin and cephalosporins including oxyimino-cephalosporin, cephamycin and aztreonam (variably). Screening of AmpC beta-lactamase determinants in both commensal and pathogenic *E. coli* isolates in livestock is important to reveal the resistance status of the bacteria. Therefore, we aimed to investigate the AmpC beta-lactamase producing *E. coli* isolates in cattle and sheep populations in Burdur, Turkey. The fecal samples were collected from 250 Holstein cows, older than 12 months of age and apparently healthy, and from 225 sheep from different breeds, older than 6 months of age and apparently healthy. After selective isolation and identification of the agent in coliform/*E. coli* selective medium supplemented with cefotaxime (2 µg/mL) or ceftazidim (2 µg/mL), the cefoxitin resistant *E. coli* isolates were determined by agar disc diffusion test (ADDT). Then, *pAmpC* beta-lactamase genes were determined by multiplex polymerase chain reaction (PCR) as gold standart test for *pAmpC* beta-lactamase producing *E. coli*. Finally, the isolates were characterized by PCR for phylogeny and Enterohemorrhagic/Shiga toxin producing *E. coli* (EHEC/STEC) related virulence genes. Totally 17 (6.8%) cattle fecal samples were found positive for *pAmpC* beta-lactamase producing *E. coli*. None of the sheep fecal samples yielded culture positive results for the bacteria of interest. Among the *E. coli* isolates, only *CIT* (origin, *Citrobacter freundii*) family *pAmpC* gene was found. The predominant phylogenetic group was found as group A and only *eae* gene was detected in only one *E. coli* isolate. Multidrug resistance (MDR) was observed in 7 (41.2%) isolates. Consequently, the present study revealed that *pAmpC* beta-lactamase producing *E. coli*, with MDR and low phylogenetic group diversity, exists in cattle population, but not in sheep population.

**Keywords:** Beta-lactamase, *Escherichia coli*, intimin, *pAmpC*, Phylogeny, Ruminant

## Sığır ve Koyunlarda Plasmidik AmpC Beta Laktamaz Üreten *Escherichia coli* Taşıyıcılığı ve İzolatların Antibiogram Profilleri, Filogenetik ve Virulans Yönünden Karakterizasyonu

## Öz

*Escherichia coli* tarafından AmpC beta laktamaz enzim üretimi penisilinlere, oksimino sefalosporinler dahil tüm sefalosporinlere, sefamisinlere ve değişik olmakla birlikte aztreonama direnç sağlar. Çiftlik hayvanlarında komensal ve patojenik *E. coli* izolatlarında AmpC beta laktamazların taranması bakterilerdeki antibiyotik dirençliliğinin durumunu göstermesi açısından önemlidir. Bu nedenle, Burdur ilindeki sığır ve koyun popülasyonunda AmpC beta laktamaz üreten *E. coli* yaygınlığını ortaya çıkarmayı amaçladık. Bu çalışmada, 12 aylık yaştan daha büyük ve sağlıklı görünümdeki 250 Holştayn ırkı sığır ve 6 aylıktan daha büyük ve sağlıklı görünümdeki 225 değişik ırktan koyundan dışkı örneği toplandı. Sefotaksim (2 µg/mL) veya seftazidim (2 µg/mL) ilave edilmiş Koliform/*E. coli* besi yerinde selektif izolasyon ve identifikasyon gerçekleştirildikten sonra, agar disk difüzyon testi (ADDT) ile sefoksitine dirençli *E. coli* izolatları belirlendi. Takiben *pAmpC* beta laktamaz genleri, *pAmpC* beta laktamaz üreten *E. coli* belirlenmesi için altın standart test olan multipleks polimeraz zincir reaksiyonu (PZR) ile belirlendi. Son olarak, izolatlar PZR ile filogenetik ve enterohemorajik/Siga toksin üreten *E. coli* (EHEC/STEC) virulans genleri açısından karakterize edildi. Toplam 17 (%6.8) sığır dışkı örneği *pAmpC* beta laktamaz üreten *E. coli* yönünden pozitif bulunurken koyun örneklerinin tümü negatif bulundu. İzolatlarda sadece *CIT* ailesi *pAmpC* geni tespit edildi. İzolatlarda en yaygın filogenetik grubun grup A olduğu ve sadece 1 izolatta *eae* virulans geninin olduğu tespit edildi. Çoklu antibiyotik dirençliliği 7 (%41.2) izolatta tespit edildi. Sonuç olarak, bu çalışma *pAmpC* beta laktamaz üreten *E. coli*'nin koyunlarda bulunmadığı ve sığırlarda çoklu antibiyotik dirençliliğine sahip ve az sayıda filogenetik çeşitlilikte var olduğu belirlendi.

**Anahtar sözcükler:** Beta laktamaz, *Escherichia coli*, Intimin, *pAmpC*, Filogenetik, Ruminant



## Correspondence



+90 248 2132063



pehlivanoglu@mehmetakif.edu.tr

## INTRODUCTION

Beta-lactamase enzymes that inactivate the beta-lactam antibiotics by hydrolysing the beta-lactam ring of the antibiotic [1,2] possess highly heterogeneous character in nature. They were divided into several groups for classification that is updated regularly by the researchers [3,4]. Several classification schemes for bacterial beta-lactamases have been described. One of them was based on the activity of the beta-lactamases against different beta-lactam antimicrobials [5]. The other scheme developed by Ambler divides the beta-lactamase enzymes into four classes as A, B, C, and D, according to their amino acid sequence differences [6]. The group of beta-lactamases classified as Ambler Class C and named AmpC beta-lactamases can confer resistance to penicillins and cephalosporins including oxyimino-cephalosporins (e.g., cefotaxime, ceftazidime and ceftriaxone), cephamycins (e.g., cefoxitin and cefotetan), and aztreonam (variably) [5,7]. It has been reported that use of beta-lactams for treatment of several infections causes development of AmpC beta-lactamase producing *E. coli* isolates in animal and human intestinal microflora. This casual use also triggers an increase in AmpC beta-lactamase production in Gram-negative pathogens in humans and animals due to the horizontal transfer of resistance genes [8,9].

The genes encoding AmpC beta-lactamases can be located on a conjugative plasmid or chromosome of a Gram-negative bacterium [7]. Plasmid mediated AmpC beta-lactamases (pAmpC) are composed of 6 families which were formed based on amino acid sequences. These families are named as ACC (Ambler class C), CIT (origin, *Citrobacter freundii*), DHA (site of discovery, Dhahran hospital in Saudi Arabia), EBC (origin, *Enterobacter cloacae*), FOX (resistance to cefoxitin) and MOX (resistance to moxalactam). Unlike to extended-spectrum beta-lactamases (ESBL), AmpC beta-lactamases can not be inhibited by beta-lactamase inhibitors (clavulanic acid and tazobactam) [7,8].

*Escherichia coli* strains causing diarrhea in human have been classified into several pathotypes based on virulence characteristics and infection mechanisms. There have been described 5 main intestinal pathogenic *E. coli* strains named as enteropathogenic *E. coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), enteroaggregative *E. coli* (EAEC), enterotoxigenic *E. coli* (ETEC) and enteroinvasive *E. coli* (EIEC). EHEC strains are responsible for bloody diarrhoea, haemorrhagic colitis (HC) and the Haemolytic Uraemic Syndrome (HUS) in human and can be transmitted to human by consumed food [10]. All are life threatening infections for human. On the other hand, animals especially cattle are known the reservoir of EHEC/Shiga toxin producing strains (STEC) and especially carriage status of O157:H7 strains have been revealed by several researchers in cattle [11]. Therefore, it is important to investigate the multidrug resistant *E. coli* isolates, such as ampC beta-lactamase producing *E. coli*, for EHEC/STEC virulence determinants to reduce the fecal

shedding of such *E. coli* isolates in animals that prevents fecal contamination of food of animal origin.

The studies conducted in several countries in the world report the existence and prevalence of AmpC beta-lactamase producing Gram-negative bacteria isolated from livestock [2,12-15]. In Turkey, Pehlivanoglu [16] reported the presence of pAmpC producing *E. coli* in laying hens, Aslantaş et al. [17] reported in cattle, Gumus et al. [18] reported in dogs and cats and Aslantas and Yilmaz [19] reported in dogs, but more studies are needed to reveal the true prevalence of AmpC producing *E. coli* in Turkey. Hence, the present study was carried out to investigate the existence of pAmpC beta-lactamase producing *E. coli* isolates in healthy cattle and sheep in Burdur, Turkey and to characterize the isolates for antibiotic susceptibility pattern, phylogeny and virulence.

## MATERIAL and METHODS

### Sampling

Approximate sample size of the study was determined to be 138 using a 10% expected field prevalence [16,17] at the 95% confidence level and the desired absolute precision of 5% [20], but more animals were included to the present study for higher precise results. Twenty dairy cattle and 12 sheep farms with no close contact to cattle farms were selected randomly from different locations of Burdur. Approximately 50% of animals were selected randomly from each cattle and sheep farms. Total 250 Holstein cows, older than 12 months of age and apparently healthy, and 225 sheep from different breeds, older than 6 months of age and apparently healthy, were included in the study. Fecal samples (at least 5 grams) were collected from rectum of the animals by using separate disposable examination gloves for each animal. The fecal samples were put into sterile screw-top vials, transported to the laboratory on ice in a cooler within 2 h and kept at 4°C until processing within 24 h. The protocol for fecal collection from animals in the present study was approved by Burdur Mehmet Akif Ersoy University (Turkey) Animal Care and Use Committee (approval number: 07.09.2012/05).

### Selective Isolation

Isolation was initiated with preparation of a 10% suspension of each fecal sample in buffered peptone water (Lab M, UK) and incubation at 37°C for 24 h under aerobic conditions. Fifty microliters from each suspension was plated onto Brilliance *E. coli*/coliform Selective Agar (Oxoid, UK) supplemented with cefotaxime (CTX, 2 µg/mL) (Sigma Aldrich, Germany) or ceftazidime (CAZ, 2 µg/mL) (Sigma Aldrich, Germany) and the plates were incubated at 37°C for 24 h under aerobic conditions.

Presumptive *E. coli* colonies (purple or blue colour) from each plate (one colony from the selective agar with CTX and one colony from the selective agar with CAZ) per culture

positive fecal sample were selected randomly. Identification of the suspicious colonies were carried out by the biochemical tests<sup>[21]</sup>. Finally, molecular confirmation of the *E. coli* isolates were performed by PCR<sup>[22]</sup> after DNA extraction yielded by boiling method<sup>[23]</sup> (Table 1).

#### Determination of the Presumptive AmpC Beta-lactamase Producing *E. coli*

Firstly, the *E. coli* isolates were tested in terms of ESBL production by agar disc diffusion test (ADDT)<sup>[24]</sup>. In this test, aztreonam (ATM, 30 µg), cefotaxime (CTX, 30 µg), cefpodoxime (CPD, 10 µg), ceftazidime (CAZ, 30 µg) and ceftriaxone (CRO, 30 µg) discs were used<sup>[24]</sup>. The isolate resistant to at least one of them were further tested with ESBL confirmatory test<sup>[24]</sup> and 34 isolates found positive

for ESBL production were excluded from the study. Then, non-ESBL-producing isolates were tested for ceftaxitin resistance by ADDT for phenotypic determination of AmpC beta-lactamase producers<sup>[24,25]</sup>. ADDT was performed by plating of each *E. coli* isolates with an inoculum (McFarland turbidity 0.5) on Mueller Hinton Agar (MHA) (Oxoid, UK) plates followed by the disc placement of ceftaxitin (FOX, 30 µg) (Oxoid, UK). The plates were incubated at 37°C for 24 h. Inhibition zone diameter lower than 18 mm was accepted for the evidence of FOX resistance<sup>[24]</sup>.

#### PCR Analysis of Plasmid Mediated AmpC Beta-lactamase Genes (pAmpC)

As the gold standard test for determination of pAmpC producing *E. coli*, PCR was performed for pAmpC genes

Target Gene	Primer Sequence (5'-----3')	Amplicon (bp)	Reference
MOX	F-GCTGCTCAAGGAGCACAGGAT R-CACATTGACATAGGTGTGGTGC	520	Perez-Perez and Hanson <sup>[8]</sup>
CIT	F-TGGCCAGAAGTACAGGCAAA R-TTTCTCCTGAACGTGGCTGGC	462	Perez-Perez and Hanson <sup>[8]</sup>
DHA	F-AACTTTCACAGGTGTGCTGGGT R-CCGTACGCATACTGGCTTTGC	405	Perez-Perez and Hanson <sup>[8]</sup>
ACC	F-AACAGCCTCAGCAGCCGGTTA R-TTCGCCCAATCATCCCTAGC	346	Perez-Perez and Hanson <sup>[8]</sup>
EBC	F-TCGGTAAAGCCGATGTTGCGG R-CTTCCACTGCGGCTGCCAGTT	302	Perez-Perez and Hanson <sup>[8]</sup>
FOX	F-AACATGGGGTATCAGGGAGATG R-CAAAGCGCGTAACCGGATTGG	190	Perez-Perez and Hanson <sup>[8]</sup>
<i>chuA</i>	F-GACGAACCAACGGTCAGGAT R-TGCCGCCAGTACCAAAGACA	279	Clermont et al. <sup>[26]</sup>
<i>YjaA</i>	F-TGAAGTGTGAGGAGACGCTG R-ATGGAGAATGCGTTCCTCAAC	211	Clermont et al. <sup>[26]</sup>
TspE4.C2	F-GAGTAATGTCGGGGCATTCA R-CGCGCCAACAAAGTATTACG	152	Clermont et al. <sup>[26]</sup>
16S rRNA	F-CCCCTGGACGAAGACTGAC R-ACCGCTGGCAACAAAGGATA	401	Wang et al. <sup>[22]</sup>
<i>rfbO157</i>	F-CAGGTGAAGGTGGAATGGTTGTC R-TTAGAATTGAGACCATCCAATAAG	296	Bai et al. <sup>[27]</sup>
<i>fliCH7</i>	F-GCTGCAACGGTAAGTGAT R-GGCAGCAAGCGGTTGGT	948	Wang et al. <sup>[22]</sup> , Osek <sup>[28]</sup>
<i>stx1</i>	F-TGTCGCATAGTGAACCTCA R-TGCGCACTGAGAAGAAGAGA	655	Bai et al. <sup>[27]</sup>
<i>stx2</i>	F-CCATGACAACGGACAGCAGTT R-TGTCGCCAGTTATCTGACATTC	477	Bai et al. <sup>[27]</sup>
<i>eae</i>	F-CATTATGGAACGGCAGAGGT R-ACGGATATCGAAGCCATTTC	375	Bai et al. <sup>[27]</sup>
<i>ehxA</i>	F-GCGAGCTAAGCAGCTTGAAT R-CTGGAGGCTGCACTAACTCC	199	Bai et al. <sup>[27]</sup>
<i>espP</i>	F-GATTACAGCACGCATTCATGGTAT R-TCCAGGCATCCTCAGTGACA	73	Posse et al. <sup>[29]</sup>
<i>katP</i>	F-GAAGTCATATATCGCCGGTTGAA R-GTCATTCAGGAACGGTGAGATC	73	Posse et al. <sup>[29]</sup>
<i>saa</i>	F-CGTGATGAACAGGCTATTGC R-ATGGACATGCCTGTGGCAAC	119	Paton and Paton <sup>[30]</sup>

F: Forward, R: Reverse, bp: base pair

according to the method developed by Perez-Perez and Hanson<sup>[8]</sup>. The PCR protocol was modified slightly in our laboratory as follow: Two sets of triplex PCR (set 1: ACC, CIT, FOX and set 2: DHA, EBC, MOX) were established for detection of *pAmpC* genes. The first triplex PCR was adjusted as 25 µL consisted of; 50 mM KCl, 0.2 mM each dNTP, 1.5 mM MgCl<sub>2</sub>, 0.4-0.6 µM primer sets (specific for FOX, ACC and CIT, respectively), 1.25 U of Taq DNA polymerase (Thermo Scientific) and 2 µL template DNA. The second triplex PCR was adjusted as 25 µL consisted of; 50 mM KCl, 0.2 mM each dNTP, 1.5 mM MgCl<sub>2</sub>, 0.5-0.6 µM primer sets (specific for EBC, DHA and MOX, respectively), 1.25 U of Taq DNA polymerase (Thermo Scientific) and 2 µL template DNA. Thermal cycling conditions for both of triplex PCRs were 5 min at 94°C for initial denaturation, followed by 35 cycles of 45 sec at 94°C, 45 sec at 64°C and 1 min at 72°C, and a final elongation step of 7 min at 72°C. The primer sequences used were presented in *Table 1*.

### Antibiotic Susceptibility Profiles, Phylogroups and Virulence Genes of the Isolates

Susceptibility of pAmpC beta-lactamase producing *E. coli* isolates to beta-lactam antibiotics and to other classes of antibiotics were determined by ADDT<sup>[24,31,32]</sup>. The beta-lactams antibiotic discs (Oxoid, UK) tested were ampicillin (AMP, 10 µg), cefepime (FEP, 30 µg), cefuroxime sodium (CXM, 30 µg), cephalothin (CEF, 30 µg) and imipenem (IPM, 10 µg). The antibiotics (Oxoid, UK) from other classes tested were chloramphenicol (C, 30 µg), ciprofloxacin (CIP, 5 µg), enrofloxacin (ENR, 5 µg), florfenicol (FFC, 30 µg), gentamicin (CN, 10 µg), kanamycin (K, 30 µg), nalidixic acid (NA, 30 µg), streptomycin (S, 10 µg), sulfamethoxazole-trimethoprim (SXT, 25 µg) and tetracycline (TE, 30 µg). *E. coli* ATCC 25922 strain was used as the control strain in ADDT. The inhibition zone diameters were evaluated according to CLSI critical zone diameters in CLSI document M10 0-S26<sup>[24]</sup>, M31-A3<sup>[31]</sup> and VET01-S2<sup>[32]</sup>. Based on the results, the isolates were classified as resistant, intermediate or susceptible. In the present study, a pAmpC beta-lactamase producing *E. coli* isolate that was resistant to at least 3 different classes of antibiotics excluding beta-lactams was accepted as multidrug-resistant (MDR) strain.

The phylogroups (groups A, B1, B2 and D) of the *E. coli* isolates were determined according to a triplex PCR protocol as described elsewhere<sup>[26]</sup>, with the modified PCR conditions by Higgins et al.<sup>[33]</sup>. The triplex PCR is based on the amplification of a 279 bp fragment of the *chuA* gene, 211 bp fragment of the *yjaA* gene and 152 bp fragment of TspE4.C2 (a noncoding DNA region of *E. coli* genome). The phylogenetic groups of the isolates were assigned according to following criteria: the phylogenetic group A (*chuA*-, TspE4.C2-), B1 (*chuA*-, TspE4.C2+), B2 (*chuA*+, *yjaA*+), or D (*chuA*+, *yjaA*-). Additionally, phylogenetic subgroups (A: A<sub>0</sub> and A<sub>1</sub>; B2: B2<sub>2</sub> and B2<sub>3</sub>; D: D<sub>1</sub> and D<sub>2</sub>) were investigated as described by Escobar-Páramo et al.<sup>[34]</sup>. *E. coli* ATCC 25922 was used as positive control strain

(*chuA*+, *yjaA*+ and TspE4.C2+) in the triplex PCR.

The pAmpC beta-lactamase producing *E. coli* isolates were screened by PCR for serotype O157:H7 (*rfbO157* and *fliCH7* genes)<sup>[27,28]</sup> and *eae* (intimin, attaching and effacing protein), *ehxA* (enterohemolysin), *espP* (extra-cellular serine protease), *katP* (catalase-peroxidase), *saa* (autoagglutinating adhesin), *stx1* (Shiga toxin 1) and *stx2* (Shiga toxin 2) to determine if the isolates were Enterohemorrhagic *E. coli* (EHEC)<sup>[27,29,30]</sup>.

## RESULTS

As the results of culture of cattle fecal samples, presumptive *E. coli* colonies were observed on at least one of both media (supplemented with CTX or CAZ) from 51 fecal samples. All colonies were identified as *E. coli* by phenotypic tests and PCR. After ESBL confirmatory test, *E. coli* isolates from 34 fecal samples were separated as ESBL-producing isolates. The remaining *E. coli* isolates (non-ESBL producers) were from 17 fecal samples and growth of *E. coli* colonies on these fecal samples (n=17) were observed on both medium (supplemented with CTX or CAZ) and therefore total 34 non-ESBL-producing *E. coli* were obtained. All of 34 non-ESBL-producing *E. coli* isolates were found to be resistant to ceftiofur by ADDT and therefore they were accepted as potential AmpC producers. In the present study, both potential AmpC beta-lactamase producing *E. coli* isolates (one from selective agar with CTX and the other one from the selective agar with CAZ) from a single fecal sample showed the same antibiotic susceptibility profile and the same phylogenetic group in all of the fecal samples. Therefore, the prevalence was estimated as 6.8% (17/250) for cattle in the study. *E. coli* was not isolated from sheep fecal samples.

All *E. coli* isolates from cattle harbored only *CIT* family *pAmpC* gene (*Fig. 1*). In total, 5 (25%, 5/20) cattle herds were found positive in terms of carrying pAmpC beta-lactamase producing *E. coli* isolates (*Table 2*).

According to phylogenetic analysis by PCR, 11 (11/17, 64.7%) *E. coli* isolates were found belong to group A (subgroup A<sub>1</sub>), 3 (3/17, 17.6%) isolates to group D (subgroup D<sub>1</sub>), 2 (2/17, 11.8%) isolates to group B2 (subgroup B2<sub>2</sub>) and 1 (1/17, 5.9%) isolate to group B1 (*Table 2*).


In total, 7 of 17 (41.2%) pAmpC beta-lactamase producing *E. coli* isolates were found MDR. Among the MDR isolates, 3 isolates belonged to phylogroup A (subgroup A<sub>1</sub>), one isolate to phylogroup B1 and one isolate to D (subgroup D<sub>1</sub>) (*Table 2*). The highest resistance was found against TET (9/17, 52.9%) whereas the lowest resistance was against CIP, ENR and NA (1/17, 5.9%). All isolates were susceptible to FEP and IPM (*Table 3*).

Among the virulence genes screened among the isolates, only *eae* (intimin) gene was detected in only one isolate

**Table 2.** Distribution of the pAmpC beta-lactamase producing *E. coli* isolates (cattle) according to herds, phylogenetic group and antibiogram profiles

Farm No	<i>E. coli</i> Isolates (n)	<i>E. coli</i> Isolates (n): Phylogenetic Group	Resistance Profile	blapAmpC Gene Family
3	8	7:A (A <sub>1</sub> )	-	CIT
		1:B2 (B2 <sub>2</sub> )	-	CIT
6	1	A (A <sub>1</sub> )	CN, S, K, FFC, C, TE*	CIT
7	6	1:A (A <sub>1</sub> )	TE	CIT
		1:B1	CN, S, K, SXT, NA, ENR, CIP, FFC, C, TE*	CIT
		1:B2 (B2 <sub>2</sub> )	S, K, TE	CIT
		3:D (D <sub>1</sub> )	S, SXT, TE*	CIT
8	1	A (A <sub>1</sub> )	CN, S, K, SXT, FFC, C, TE*	CIT
9	1	A (A <sub>1</sub> )	CN, S, K, FFC, C, TE*	CIT

\* Multidrug resistant isolate (MDR, resistant to at least 3 classes of antibiotics except beta-lactam antibiotics). C: chloramphenicol, CIP: ciprofloxacin, ENR: enrofloxacin, FFC: florfenicol, CN: gentamicin, K: kanamycin, NA: nalidixic acid, S: streptomycin, SXT: sulfamethoxazole-trimethoprim, TE: tetracycline



**Fig 1.** Results of PCR test performed for pAmpC beta-lactamase genes of *E. coli* isolates (cattle). M: Marker (a:500 bp, b:400 bp, c:300 bp, d:200 bp, e:100 bp), Lane 1-12: *E. coli* isolates positive for CIT type pAmpC beta-lactamase gene (462 bp), Lane 13: negative control

**Table 3.** Antibiotic susceptibilities of pAmpC beta-lactamase producing *E. coli* isolates (cattle)

Beta- Lactams	pAmpC Producing <i>E. coli</i> (n=17)		Other Antibiotics	pAmpC Producing <i>E. coli</i> (n=17)	
	R (n)	I (n)		R(n)	I (n)
AMP	17	0	CN	4	0
ATM	17	n/a	K	5	0
FEP	0	0	S	8	1
CTX	17	n/a	CIP	1	0
CPD	17	n / a	ENR	1	0
CAZ	17	n/a	NA	1	0
CRO	17	n / a	TE	9	0
CXM	13	0	SXT	5	0
CEF	17	0	FFC	4	0
IPM	0	0	C	4	0

n/a: not applicable, R: resistant, I: intermediate, AMP: ampicillin, ATM: aztreonam, CAZ: ceftazidime, FEP: cefepime, CPD: cefpodoxime, CRO: ceftriaxone, CXM: cefuroxime, CEF: cephalothin, CTX: cefotaxime, FOX: ceftiofur, IPM: imipenem, C: chloramphenicol, CIP: ciprofloxacin, ENR: enrofloxacin, FFC: florfenicol, CN: gentamicin, K: kanamycin, NA: nalidixic acid, S: streptomycin, SXT: sulfamethoxazole-trimethoprim, TE: tetracycline

from Farm 3. This *E. coli* isolate belonged to B2<sub>2</sub> phylogenetic group and was not resistant to any of the antibiotics (except beta lactams) tested. None of the pAmpC beta-lactamase producing *E. coli* isolates was O157:H7 serotype of *E. coli*.

## DISCUSSION

The real prevalence of pAmpC beta-lactamase producing *E. coli* is still unknown in healthy cattle and sheep in Turkey. There is only one local study conducted on this topic in healthy cattle in Turkey and it was found only one *E. coli* isolate carrying *ampC* (*cmv*) gene out of 312 cattle rectal swab samples [17]. On the other hand, there is no report for pAmpC beta-lactamase producing *E. coli* in healthy sheep in Turkey. Even though some studies have shown the existence of AmpC beta-lactamase producing *E. coli* and *AmpC* genes on cattle origin food products (cheese, meat, and milk) in different parts of Turkey [35-37], these studies do not reflect exactly the extent of these isolates in live animals in Turkey due to possible contamination of the animal origin food during processing. Therefore, the present study conducted have given additional information about the presence of AmpC beta-lactamase producing *E. coli* in cattle and sheep in Turkey.

Although we detected AmpC beta-lactamase producing *E. coli* in 17 cattle, no sheep was detected positive for AmpC beta-lactamase producing *E. coli*. This can be attributed to use of the beta-lactams and other classes of antibiotics (aminoglycosides, beta-lactams, phenicols, quinolones, sulfamethoxazole-trimethoprim and tetracycline) more widely in the prevention and treatment of wide variety of infections (mastitis, lameness, calf diarrhea, metritis, arthritis, pneumoniae, salmonellosis, urinary tract infections, septicemia, etc.) in cattle population than sheep population in Turkey and some of them may cause co-selection of AmpC beta-lactamase producing *E. coli* isolates in gut microflora. It has been known that *ampC* genes are located on a large plasmid together with other antimicrobial resistance genes such as the genes responsible for aminoglycosides, phenicols, quinolones, sulfamethoxazole-trimethoprim and tetracycline resistances and frequent use of these antibiotics in livestock for several purposes leads the selection pressure for AmpC beta-lactamase producing Gram-negative bacteria in gut microflora [2]. In line with this it was detected co-resistance to at least one of these antibiotics in 9 (9/17, 52.9%) isolates and MDR in 7 (41.2%) isolates in this study.

*Escherichia coli* isolates obtained in this study were found fall into four main phylogenetic groups (A, B1, B2 and D). It is known that *E. coli* strains belonging to group A and B1 are primarily found in the commensal microflora [26,34]. The pathogen *E. coli* strains associated with extra-intestinal infections and diarrhea mainly belong to B2 and D groups [26,34]. Later, Escobar-Paramo et al. [34] stated

phylogenetic subgroups (A: A<sub>0</sub> and A<sub>1</sub>; B2: B2<sub>2</sub> and B2<sub>3</sub>; D: D<sub>1</sub> and D<sub>2</sub>). Likewise, in the present study, phylogenetic analysis of *E. coli* isolates showed that group A (subgroup A<sub>1</sub>) (n=11) is the predominant group, followed by group D (subgroup D<sub>1</sub>) (n=3), group B2 (subgroup B2<sub>2</sub>) (n=2) and group B1 (n=1). On the other hand, the reports indicate that *E. coli* strains from B2 and D phylogroups possess more virulence factors but less MDR pattern than A and B1 phylogroups [38,39]. Similarly, in the present study the *E. coli* isolates from A and B1 phylogroups showed resistance to more antibiotics than the B2 and D phylogroup isolates and EHEC/STEC related virulence gene (*eae*, intimin) detected was found in the *E. coli* isolate belonging to B2<sub>2</sub> phylogroup with no co-resistance to other classes of antibiotics. The *eae* gene encodes the intimin protein on the surface of EPEC/STEC/EHEC isolates and it is located on the locus of enterocyte effacement (LEE) pathogenicity island. The intimin protein is important for intimate attachment to the intestinal mucosa and the formation of the attaching and effacing lesions in EPEC and STEC/EHEC infections [40]. Therefore, it is possible to state that the *eae* gene positive and pAmpC beta-lactamase producing *E. coli* isolate from B2<sub>2</sub> phylogenetic group determined in cattle in this study can be pathogenic for both human and calf even though this isolate is not a STEC/EHEC isolate.

Overall, based on the similarity of phylogenetic analysis results and antibiogram profiles of the isolates, three farms (Farm 6, 8 and 9) had only one isolate, one farm (Farm 3) had 2 different isolates and one farm (Farm 7) had 4 different isolates. Additionally, all isolates had the same *blapAmpC* gene family (*CIT*). Hence, it can be stated that few parent *E. coli* strains with the same *pAmpC* gene (*CIT*) were circulating in the cattle farms in Burdur, Turkey.

It is generally accepted that food producing animals serve as reservoir for MDR *E. coli* strains and they can be transmitted to human by direct contact and/or via food chains. This issue has also been considered for AmpC beta-lactamase producing *E. coli* since there are many studies showing the similar *pAmpC* genes and plasmids in both animal and animal owners or farm workers [41-43]. Therefore, we can mention the possible health risk for people close contact to the cattle population in the present study.

In conclusion, the present study showed the absence of pAmpC beta-lactamase producing *E. coli* in sheep population and presence of few multi-drug resistant pAmpC beta-lactamase producing *E. coli* strains with only one type *pAmpC* gene family (*CIT*) in cattle population in Burdur, Turkey. However, more studies are needed to reveal and understand the course of prevalence of pAmpC beta-lactamase producing *E. coli* (pathogen and commensal) and diversity in *pAmpC* genes in livestock populations in Turkey. The other point that should be considered, as known, emergence of *E. coli* isolates possessing *pAmpC* genes may also bring the increase in production of the AmpC beta-lactamases in other Gram-negative bacteria due to horizontal

transfer of plasmids between Gram-negative bacteria species. Hence, the necessary preventive measurements should be taken, for examples, livestock sector workers and veterinarians should be informed regularly about increase in antimicrobial-resistant strains and proper selection of antimicrobials should be provided in the treatment of the infections in animals. Also, monitoring should be performed for antimicrobial resistance levels to limit the escalating trend in antimicrobial resistance and the emergence of resistance traits in genetic material of Gram-negatives.

## DECLARATION OF CONFLICTING INTERESTS

The authors declare no conflict of interest.

## REFERENCES

- Frere JM:** Beta-lactamases and bacterial resistance to antibiotics. *Mol Microbiol*, 16, 385-395, 1995. DOI: 10.1111/j.1365-2958.1995.tb02404.x
- Seiffert SN, Hilty M, Perreten V, Endimiani A:** Extended-spectrum cephalosporin-resistant gram-negative organisms in livestock: An emerging problem for human health? *Drug Resist Updat*, 16, 22-45, 2013. DOI: 10.1016/j.drup.2012.12.001
- Bush K, Jacoby GA:** Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 54 (3): 969-976, 2010. DOI: 10.1128/AAC.01009-09
- Vardanyan R, Hruby V:** Antibiotics. In, Synthesis of Best Seller Drugs. 573-643, Elsevier B.V., 2016.
- Bush K, Jacoby GA, Medeiros AA:** Functional classification scheme for  $\beta$ -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother*, 39 (6): 1211-1233, 1995. DOI: 10.1128/AAC.39.6.1211
- Ambler RP:** The structure of  $\beta$ -lactamases. *Philos Trans R Soc Lond B Biol Sci*, 289 (1036): 321-331, 1980. DOI: 10.1098/rstb.1980.0049
- Jacoby GA:** AmpC  $\beta$ -lactamases. *Clin Microbiol Rev*, 22, 161-182, 2009. DOI: 10.1128/CMR.00036-08
- Pérez-Pérez FJ, Hanson ND:** Detection of plasmid-mediated AmpC  $\beta$ -lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol*, 40, 2153-2162, 2002. DOI: 10.1128/JCM.40.6.2153-2162.2002
- Lerner A, Matthias T, Aminov R:** Potential effects of horizontal gene exchange in the human gut. *Front Immunol*, 8:1630, 2017. DOI: 10.3389/fimmu.2017.01630
- Bugarel M, Martin A, Fach P, Beutin L:** Virulence gene profiling of enterohemorrhagic (EHEC) and enteropathogenic (EPEC) *Escherichia coli* strains: A basis for molecular risk assessment of typical and atypical EPEC strains. *BMC Microbiol*, 11:142, 2011. DOI: 10.1186/1471-2180-11-142
- Venegas-Vargas C, Henderson S, Khare A, Mosci RE, Lehnert JD, Singh P, Ouellette LM, Norby B, Funk JA, Rust S, Bartlett PC, Grooms D, Manning SD:** Factors associated with Shiga toxin-producing *Escherichia coli* shedding by dairy and beef cattle. *Appl Environ Microbiol*, 82, 5049-5056, 2016. DOI: 10.1128/AEM.00829-16
- Asai T, Masani K, Sato C, Hiki M, Usui U, Baba K, Ozawa M, Harada K, Aoki H, Sawada T:** Phylogenetic groups and cephalosporin resistance genes of *Escherichia coli* from diseased food-producing animals in Japan. *Acta Vet Scand*, 53:52, 2011. DOI: 10.1186/1751-0147-53-52
- Hille K, Fischer J, Falgenhauer L, Sharp H, Brenner GM, Kadlec K, Friese A, Schwarz S, Imirzalioglu C, Kietzmann M, Von Münchhausen C, Kreienbrock L:** On the occurrence of extended-spectrum and AmpC-beta-lactamase-producing *Escherichia coli* in livestock: Results of selected European studies. *Berl Munch Tierarztl Wochenschr*, 127 (9-10): 403-411, 2014.
- EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control):** The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2017. *EFSA J*, 17 (2):e05598, 2019. DOI: 10.2903/j.efsa.2019.5598
- Tewari R, Mitra S, Ganaie F, Das S, Chakraborty A, Venugopal N, Shome R, Rahman H, Shome BR:** Dissemination and characterisation of *Escherichia coli* producing extended-spectrum  $\beta$ -lactamases, AmpC  $\beta$ -lactamases and metallo- $\beta$ -lactamases from livestock and poultry in Northeastern India: A molecular surveillance approach. *J Glob Antimicrob Resist*, 17, 209-215, 2019. DOI: 10.1016/j.jgar.2018.12.025
- Pehlivanoglu F:** Existence of plasmid mediated AmpC beta-lactamase-producing *Escherichia coli* isolates in healthy laying hens. *Van Vet J*, 28 (2): 63-67, 2017.
- Aslantaş Ö, Elmaccioğlu S, Yılmaz EŞ:** Prevalence and characterization of ESBL and AmpC-producing *Escherichia coli* from cattle. *Kafkas Univ Vet Fak Derg*, 23, 63-67, 2017. DOI: 10.9775/kvfd.2016.15832
- Gumus B, Celik B, Kahraman BB, Siğirci BD, Ak S:** Determination of extended spectrum beta-lactamase (ESBL) and AmpC beta-lactamase producing *Escherichia coli* prevalence in faecal samples of healthy dogs and cats. *Revue Med Vet*, 168, 46-52, 2017
- Aslantas O, Yilmaz ES:** Prevalence and molecular characterization of extended-spectrum beta-lactamase (ESBL) and plasmidic AmpC beta-lactamase (pAmpC) producing *Escherichia coli* in dogs. *J Vet Med Sci*, 79, 1024-1030, 2017. DOI: 10.1292/jvms.16-0432
- Thrusfield M:** Surveys. In, Veterinary Epidemiology. 3<sup>rd</sup> ed., 228-242, Blackwell Publishing, Ames, Iowa, 2007.
- Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, Woods G:** The Enterobacteriaceae. In, Koneman EW (Ed): Koneman's Color Atlas and Textbook of Diagnostic Microbiology. 6<sup>th</sup> ed., 211-302, Lippincott Williams and Wilkins, Philadelphia, 2006.
- Wang G, Clark CG, Rodgers FG:** Detection in *Escherichia coli* of the genes encoding the major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 shiga toxin family by multiplex PCR. *J Clin Microbiol*, 40, 3613-3619, 2002. DOI: 10.1128/JCM.40.10.3613-3619.2002
- Pehlivanoglu F, Turutoglu H, Ozturk D:** CTX-M-15-type extended-spectrum beta-lactamase-producing *Escherichia coli* as causative agent of bovine mastitis. *Foodborne Pathog Dis*, 13 (9): 477-482, 2016. DOI: 10.1089/fpd.2015.2114
- CLSI (Clinical and Laboratory Standards Institute):** Performance standards for antimicrobial susceptibility testing. 26<sup>th</sup> Informational Supplement, CLSI Document M100-S26, Pennsylvania, USA, 2016.
- Polzfuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M:** Practical approach for reliable detection of AmpC beta-lactamase producing *Enterobacteriaceae*. *J Clin Microbiol*, 49, 2798-2803, 2011. DOI: 10.1128/JCM.00404-11
- Clermont O, Bonacorsi S, Bingen E:** Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol*, 66, 4555-4558, 2000. DOI: 10.1128/aem.66.10.4555-4558.2000
- Bai J, Paddock ZD, Shi X, Li S, An B, Nagaraja TG:** Application of a multiplex PCR to detect the seven major shiga toxin-producing *Escherichia coli* based on genes that code for serogroup-specific O-antigens and major virulence factors in cattle feces. *Foodborne Pathog Dis*, 9, 541-548, 2012. DOI: 10.1089/fpd.2011.1082
- Osek J:** Development of a multiplex PCR approach for the identification of shiga toxin-producing *Escherichia coli* strains and their major virulence factor genes. *J Appl Microbiol*, 95, 1217-1225, 2003. DOI: 10.1046/j.1365-2672.2003.02091.x
- Posse B, Zutter LD, Heyndrickx M, Herman L:** Metabolic and genetic profiling of clinical O157 and non-O157 shiga-toxin-producing *Escherichia coli*. *Res Microbiol*, 158, 591-599, 2007. DOI: 10.1016/j.resmic.2007.06.001
- Paton AW, Paton JC:** Direct detection and characterization of Shiga toxin-producing *Escherichia coli* by multiplex PCR for *stx<sub>1</sub>*, *stx<sub>2</sub>*, *eae*, *ehxA* and *saa*. *J Clin Microbiol*, 40, 271-274, 2002. DOI: 10.1128/JCM.40.1.271-274.2002
- CLSI (Clinical and Laboratory Standards Institute):** Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, Approved standard, 3<sup>rd</sup> Ed., CLSI document M31-A3, Pennsylvania, USA, 2010.
- CLSI (Clinical and Laboratory Standards Institute):** Performance

standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, 2<sup>nd</sup> informational supplement, CLSI document VET01-S2, Pennsylvania, USA, 2013.

**33. Higgins J, Hohn C, Hornor S, Frana M, Denver M, Joerger R:** Genotyping of *Escherichia coli* from environmental and animal samples. *J Microbiol Methods*, 70, 227-235, 2007. DOI: 10.1016/j.mimet.2007.04.009

**34. Escobar-Páramo P, Le Menac'h A, Le Gall T, Amorin C, Gouriou S, Picard B, Skurnik D, Denamur E:** Identification of forces shaping the commensal *Escherichia coli* genetic structure by comparing animal and human isolates. *Environ Microbiol*, 8, 1975-1984, 2006. DOI: 10.1111/j.1462-2920.2006.01077.x

**35. Pehlivanlar Onen S, Aslantas O, Yılmaz ES, Kurekci C:** Prevalence of  $\beta$ -lactamase -producing *Escherichia coli* from retail meat in Turkey. *J Food Sci*, 80 (9): M2023-M2029, 2015. DOI: 10.1111/1750-3841.12984

**36. Ozpinar H, Tekiner IH, Sarici B, Cakmak B, Gokalp F, Ozadam A:** Phenotypic characterization of ESBL- and AmpC- type beta- lactamases in *Enterobacteriaceae* from chicken meat and dairy products. *Ankara Univ Vet Fak Derg*, 64 (4): 267-272, 2017.

**37. Ozdikmenli Tepeli S, Demirel Zorba NN:** Frequency of extended-spectrum  $\beta$ -lactamase (ESBL)- and AmpC  $\beta$ -lactamase-producing *Enterobacteriaceae* in a cheese production process. *J Dairy Sci*, 101, 2906-2914, 2018. DOI: 10.3168/jds.2017-13878

**38. Smith JL, Fratamico PM, Gunther NW:** Extraintestinal pathogenic *Escherichia coli*. *Foodborne Pathog Dis*, 4 (2): 134-163, 2007. DOI: 10.1089/

fpd.2007.0087

**39. Chakraborty A, Saralaya V, Adhikari P, Shenoy S, Baliga S, Hegde A:** Characterization of *Escherichia coli* phylogenetic groups associated with extraintestinal infections in South Indian population. *Ann Med Health Sci Res*, 5 (4): 241-246, 2015.

**40. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB:** A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. *Proc Natl Acad Sci USA*, 92 (5): 1664-1668, 1995. DOI: 10.1073/pnas.92.5.1664

**41. Voets GM, Fluit AC, Scharringa J, Schapendonk C, Van Den Munckhof T, Leverstein-Van Hall MA, Stuart JC:** Identical plasmid AmpC beta-lactamase genes and plasmid types in *E. coli* isolates from patients and poultry meat in the Netherlands. *Int J Food Microbiol*, 167, 359-362, 2013. DOI: 10.1016/j.ijfoodmicro.2013.10.001

**42. Huijbers PMC, Graat EAM, Haenen APJ, Van Santen MG, Van Essen-Zandbergen A, Mevius DJ, Van Duijkeren E, Van Hoek AHAM:** Extended-spectrum and AmpC  $\beta$ -lactamase-producing *Escherichia coli* in broilers and people living and/or working on broiler farms: Prevalence, risk factors and molecular characteristics. *J Antimicrob Chemother*, 69 (10): 2669-2675, 2014. DOI: 10.1093/jac/dku178

**43. Ljungquist O, Ljungquist D, Myrenås M, Ryden C, Finn M, Bengtsson B:** Evidence of household transfer of ESBL-/pAmpC-producing *Enterobacteriaceae* between humans and dogs - A pilot study. *Infect Ecol Epidemiol*, 6:31514, 2016. DOI: 10.3402/iee.v6.31514